Katherine Chastain

1.2k total citations
45 papers, 607 citations indexed

About

Katherine Chastain is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Katherine Chastain has authored 45 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 21 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in Katherine Chastain's work include Multiple Myeloma Research and Treatments (28 papers), Protein Degradation and Inhibitors (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Katherine Chastain is often cited by papers focused on Multiple Myeloma Research and Treatments (28 papers), Protein Degradation and Inhibitors (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Katherine Chastain collaborates with scholars based in United States, Spain and Netherlands. Katherine Chastain's co-authors include Shrikant Anant, Dharmalingam Subramaniam, Prasad Dandawate, Kathleen Neville, Gaurav Kaushik, Scott J. Weir, Prabhu Ramamoorthy, Nicole Kucine, Michelle Mahler and James B. Bussel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Katherine Chastain

40 papers receiving 601 citations

Peers

Katherine Chastain
Songfu Jiang China
Oliver J. Stoetzer Germany
Giuseppa Penna Italy
Moses O. Evbuomwan United States
Fuming Zi China
Varsha Bhakta Canada
Yanmeng Li China
Dedong Cao China
Songfu Jiang China
Katherine Chastain
Citations per year, relative to Katherine Chastain Katherine Chastain (= 1×) peers Songfu Jiang

Countries citing papers authored by Katherine Chastain

Since Specialization
Citations

This map shows the geographic impact of Katherine Chastain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Chastain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Chastain more than expected).

Fields of papers citing papers by Katherine Chastain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Chastain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Chastain. The network helps show where Katherine Chastain may publish in the future.

Co-authorship network of co-authors of Katherine Chastain

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Chastain. A scholar is included among the top collaborators of Katherine Chastain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Chastain. Katherine Chastain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Yue, Xin Miao, Steven Hanson, et al.. (2025). Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma. Targeted Oncology. 20(4). 651–661. 1 indexed citations
2.
Costa, Luciano J., Laura Rosiñol, Rakesh Popat, et al.. (2024). LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES. Hematology Transfusion and Cell Therapy. 46. S515–S515.
3.
Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235. 1 indexed citations
4.
Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235.
5.
Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S548–S548. 8 indexed citations
6.
Popat, Rakesh, Ajay K. Nooka, Niels W.C.J. van de Donk, et al.. (2024). P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S80–S80. 1 indexed citations
7.
Garfall, Alfred L., Lotfi Benboubker, Katarina Uttervall, et al.. (2024). MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S549–S549. 1 indexed citations
8.
Matous, Jeffrey, Albert Oriol, Alfred L. Garfall, et al.. (2024). Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial. Blood. 144(Supplement 1). 4749–4749.
9.
Martin, Thomas G., María-Victoria Mateos, Niels W.C.J. van de Donk, et al.. (2024). Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies. Blood. 144(Supplement 1). 3331–3331.
10.
Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations
11.
Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900. 36 indexed citations
12.
Gonzalez, Elizabeth M., Atif Ahmed, Katherine Chastain, et al.. (2023). Perinucleolar Compartment (PNC) Prevalence as an Independent Prognostic Factor in Pediatric Ewing Sarcoma: A Multi-Institutional Study. Cancers. 15(8). 2230–2230. 2 indexed citations
13.
Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S224–S224. 3 indexed citations
14.
15.
Ramamoorthy, Prabhu, Sufi M. Thomas, Gaurav Kaushik, et al.. (2019). Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. Cancer Research. 79(7). 1681–1695. 44 indexed citations
16.
Ma, Yan, Jennifer Crow, Vincent S. Staggs, et al.. (2019). Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Journal of Molecular Medicine. 97(7). 957–972. 21 indexed citations
17.
Kaushik, Gaurav, Dharmalingam Subramaniam, Prasad Dandawate, et al.. (2017). Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. Journal of Hematology & Oncology. 10(1). 10–10. 141 indexed citations
18.
Parameswaran, Lalitha, Agam K. Rao, Katherine Chastain, et al.. (2017). A Case of Adult Intestinal Toxemia Botulism During Prolonged Hospitalization in an Allogeneic Hematopoietic Cell Transplant Recipient. Clinical Infectious Diseases. 66(suppl_1). S99–S102. 9 indexed citations
19.
Carpenter, Shannon L., Jennifer L. Goldman, Ashley Sherman, et al.. (2015). Clinical variables and Staphylococcus aureus virulence factors associated with venous thromboembolism in children. Thrombosis Research. 138. 69–73. 13 indexed citations
20.
Kucine, Nicole, Katherine Chastain, Michelle Mahler, & James B. Bussel. (2014). Primary thrombocytosis in children. Haematologica. 99(4). 620–628. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Songfu Jiang Breakdown of academic impact, for papers by Oliver J. Stoetzer Breakdown of academic impact, for papers by Giuseppa Penna Breakdown of academic impact, for papers by Moses O. Evbuomwan Breakdown of academic impact, for papers by Fuming Zi Breakdown of academic impact, for papers by Varsha Bhakta Breakdown of academic impact, for papers by Yanmeng Li Breakdown of academic impact, for papers by Dedong Cao
Rankless by CCL
2026